The NEONATE score predicts freedom from interstage mortality or transplant in a modern cohort

Humera Ahmed; Jeffrey B Anderson; Katherine E Bates; Carole M Lannon; David W Brown; National Pediatric Cardiology Quality Improvement Collaborative

doi:10.1017/S1047951123003542

The NEONATE score predicts freedom from interstage mortality or transplant in a modern cohort

Cardiol Young. 2023 Nov 28:1-8. doi: 10.1017/S1047951123003542. Online ahead of print.

Authors

Humera Ahmed¹, Jeffrey B Anderson², Katherine E Bates³, Carole M Lannon², David W Brown⁴; National Pediatric Cardiology Quality Improvement Collaborative

Affiliations

¹ Departments of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
² Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
³ C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI, USA.
⁴ Boston Children's Hospital, Boston, MA, USA.

PMID: 38014532
DOI: 10.1017/S1047951123003542

Abstract

Background: Derived from the National Pediatric Cardiology Quality Improvement Collaborative registry, the NEONATE risk score predicted freedom from interstage mortality or heart transplant for patients with single ventricle CHD and aortic arch hypoplasia discharged home following Stage 1 palliation.

Objectives: We sought to validate the score in an external, modern cohort.

Methods: This was a retrospective cohort analysis of single ventricle CHD and aortic arch hypoplasia patients enrolled in the National Pediatric Cardiology Quality Improvement Collaborative Phase II registry from 2016 to 2020, who were discharged home after Stage 1 palliation. Points were allocated per the NEONATE score (Norwood type-Norwood/Blalock-Taussig shunt: 3, Hybrid: 12; extracorporeal membrane oxygenation post-op: 9, Opiates at discharge: 6, No Digoxin at discharge: 9, Arch Obstruction on discharge echo: 9, Tricuspid regurgitation ≥ moderate on discharge echo: 12; Extra oxygen plus ≥ moderate tricuspid regurgitation: 28). The composite primary endpoint was interstage mortality or heart transplant.

Results: In total, 1026 patients met inclusion criteria; 61 (6%) met the primary outcome. Interstage mortality occurred in 44 (4.3%) patients at a median of 129 (IQR 62,195) days, and 17 (1.7%) were referred for heart transplant at a 167 (114,199) days of life. The median NEONATE score was 0(0,9) in those who survived to Stage 2 palliation compared to 9(0,15) in those who experienced interstage mortality or heart transplant (p < 0.001). Applying a NEONATE score cut-off of 17 points that separated patients into low- and high-risk groups in the learning cohort provided 91% specificity, negative predictive value of 95%, and overall accuracy of 87% (85.4-89.5%).

Conclusion: In a modern cohort of patients with single ventricle CHD and aortic arch hypoplasia, the NEONATE score remains useful at discharge post-Stage 1 palliation to predict freedom from interstage mortality or heart transplant.

Keywords: CHD; paediatric cardiology; risk score; single ventricle.